17 Result(s)
-
Article
Open AccessDose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials
Ponatinib, the only approved all known-BCR::ABL1 inhibitor, is a third-generation tyrosine-kinase inhibitor (TKI) designed to inhibit BCR::ABL1 with or without any single resistance mutation, including T315I, ...
-
Article
Open AccessPredictive models for health outcomes due to SARS-CoV-2, including the effect of vaccination: a systematic review
The interaction between modelers and policymakers is becoming more common due to the increase in computing speed seen in recent decades. The recent pandemic caused by the SARS-CoV-2 virus was no exception. Thu...
-
Article
Open AccessA phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents
Pevonedistat is a first-in-class, small molecular inhibitor of NEDD8-activating enzyme that has clinical activity in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Preclinical data suggest s...
-
Article
Open AccessCorrection: Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee
-
Article
Open AccessRetrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee
The phase 2 PACE (Ponatinib Ph+ ALL and CML Evaluation) trial of ponatinib showed robust long-term benefit in relapsed Philadelphia chromosome-positive (Ph+) leukemia; arterial occlusive events (AOEs) occurred...
-
Article
The Care of the Leukemic Patients in Times of SARS-CoV-2
The spread of the novel coronavirus SARS-CoV-2 and its associated disease, coronavirus disease of 2019 (COVID-19), has significantly derailed cancer care. Patients with leukemia are more likely to have severe ...
-
Article
Open AccessConcentration–QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia
This analysis evaluated the relationship between concentrations of quizartinib and its active metabolite AC886 and QT interval corrected using Fridericia’s formula (QTcF) in patients with relapsed/refractory a...
-
Article
Open AccessThird-line therapy for chronic myeloid leukemia: current status and future directions
Chronic myeloid leukemia (CML) is driven by the BCR-ABL1 fusion protein, formed by a translocation between chromosomes 9 and 22 that creates the Philadelphia chromosome. The BCR-ABL1 fusion protein is an optim...
-
Article
Open AccessSafety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study
Talacotuzumab, a humanized anti-CD123 monoclonal antibody, was evaluated in combination with decitabine in elderly patients with acute myeloid leukemia (AML) not eligible for intensive chemotherapy. A multicen...
-
Article
Open AccessTyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience
Patients with CML treated with TKI can have a life expectancy comparable to that of the general population. Due to the extended duration of TKI administration, treatment discontinuation has been increasingly s...
-
Article
Open AccessLong-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis
Myelofibrosis (MF) is a life-shortening complication of myeloproliferative neoplasms associated with ineffective hematopoiesis, splenomegaly, and progressive bone marrow (BM) fibrosis. The oral Janus kinase (J...
-
Article
Open AccessEvaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios
With high survival rates for chronic myeloid leukemia (CML) patients treated with BCR-ABL1 tyrosine kinase inhibitors (TKIs), emerging consequences, such as arterial ischemic events, require consideration when...
-
Article
Open AccessThe Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia
Increasing knowledge concerning the biology of hematologic malignancies as well as the role of the immune system in the control of these diseases has led to the development and approval of immunotherapies that...
-
Article
Open AccessClinical features of De Novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations
De novo acute myeloid leukemia (AML) with concurrent DNMT3A, FLT3 and NPM1 mutations (AML DNMT3A/FLT3/NPM1 ) has been suggested to represent a unique AML subset on the basis ...
-
Article
Open AccessOptimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing
Ruxolitinib, an oral JAK1 and JAK2 inhibitor, is approved in the US for patients with intermediate or high-risk myelofibrosis (MF), a chronic neoplasm associated with aberrant myeloproliferation, progressive b...
-
Article
Open AccessAnalysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies
Cardiac dysfunction, particularly QT interval prolongation, has been observed with tyrosine kinase inhibitors approved to treat chronic myeloid leukemia. This study examines the effects of ponatinib on cardiac...
-
Article
Open AccessIncidence of hip fractures in Salamanca, Spain. Period: 1994–2002
The incidence of hip fractures in Salamanca (Spain) has been lower than in other countries, but has shown a marked increase during the past few decades. The aim of this work is to ascertain the real incidence ...
